×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RGNX – regenxbio inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RGNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
05:13 pm
rgnx
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
3/17
04:00 pm
rgnx
Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP
Medium
Report
Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP
3/17
02:57 pm
rgnx
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Low
Report
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
3/17
02:50 pm
rgnx
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Low
Report
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
3/17
02:31 pm
rgnx
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against REGENXBIO Inc. (RGNX), Franklin BSP Realty Trust, Inc. (FBRT), and Aquestive Therapeutics, Inc. (AQST) Announced by Holzer & Holzer, LLC
Low
Report
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against REGENXBIO Inc. (RGNX), Franklin BSP Realty Trust, Inc. (FBRT), and Aquestive Therapeutics, Inc. (AQST) Announced by Holzer & Holzer, LLC
3/17
09:00 am
rgnx
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
Low
Report
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
3/16
04:00 pm
rgnx
RGNX's "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP
Low
Report
RGNX's "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP
3/16
12:00 pm
rgnx
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/12
06:18 pm
rgnx
Form 4 REGENXBIO Inc. For: Mar 10 Filed by: PAKOLA STEVE
Medium
Report
Form 4 REGENXBIO Inc. For: Mar 10 Filed by: PAKOLA STEVE
3/10
04:37 pm
rgnx
Form 144 REGENXBIO Inc. Filed by: PAKOLA STEVE
Medium
Report
Form 144 REGENXBIO Inc. Filed by: PAKOLA STEVE
3/5
04:21 pm
rgnx
Form 10-K REGENXBIO Inc. For: Dec 31
Low
Report
Form 10-K REGENXBIO Inc. For: Dec 31
3/5
07:30 am
rgnx
Form 8-K REGENXBIO Inc. For: Mar 05
Medium
Report
Form 8-K REGENXBIO Inc. For: Mar 05
2/10
06:04 am
rgnx
Form 8-K REGENXBIO Inc. For: Feb 07
Low
Report
Form 8-K REGENXBIO Inc. For: Feb 07
2/3
04:47 pm
rgnx
Form 4 REGENXBIO Inc. For: Feb 01 Filed by: PAKOLA STEVE
Low
Report
Form 4 REGENXBIO Inc. For: Feb 01 Filed by: PAKOLA STEVE
2/3
04:47 pm
rgnx
Form 4 REGENXBIO Inc. For: Feb 01 Filed by: Christmas Patrick J.
Low
Report
Form 4 REGENXBIO Inc. For: Feb 01 Filed by: Christmas Patrick J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
12.1%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
TOP News Decliners
3/11
Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
-17.1%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: